Scancell Holdings

Scancell Holdings plc develops immunotherapies for the treatment of cancer. The Company develops immunotherapies based on its ImmunoBody and Moditope technology platforms. Its ImmunoBody, SCIB1, is being developed for treatment of melanoma and is being evaluated in Phase I/II clinical trial. Its clinical trials demonstrated that SCIB1, when used as monotherapy, has an effect on tumor load, produces a melanoma-specific immune response and survival trend without serious side effects. Its ImmunoBody vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system, where inflammation is stimulated at the tumor site and the cytotoxic T-lymphocyte response, where immune system cells are primed to recognize and kill specific cells. The Moditope immunotherapy platform is based on exploiting the normal immune response to stressed cells, mediated by cluster of differentiation 4+ T cells, and harnessing this mechanism to eradicate cancer cells.
Type
Public
HQ
Nottingham, GB
Employees
10 (est)
Scancell Holdings is headquartered in Nottingham, GB

Scancell Holdings Locations

Nottingham, GB

Scancell Holdings Metrics

Scancell Holdings Summary

Market capitalization

£38.6 M

Closing share price

£0.148
Scancell Holdings's latest market capitalization is £38.6 M.

Scancell Holdings Market Value History

0.0% of current employees of Scancell Holdings are female and 100% are male.

Scancell Holdings News

Scancell Holdings Company Life

You may also be interested in